This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Madeddu, P. Articles by Olivetti, G. Search for Related Content PubMed PubMed Citation Articles by Madeddu, P. Articles by Olivetti, G. Related Collections Congestive Lipids ACE/Angiotension receptors Animal models of human disease Genetically altered mice Heart failure - basic studies Hypertrophy Cardiac development

(Hypertension. 2000;35:391.)
© 2000 American Heart Association, Inc.

Scientific Contributions

Angiotensin II Type 1 Receptor Blockade Prevents Cardiac Remodeling in Bradykinin B₂ Receptor Knockout Mice

Paolo Madeddu; Costanza Emanueli; Roberta Maestri; Maria Bonaria Salis; Alessandra Minasi; Maurizio C. Capogrossi; Giorgio Olivetti

From the National Laboratory of the National Institute of Biostructures and Biosystems (P.M., C.E., M.B.S.), Osilo; Laboratorio di Patologia Vascolare (C.E., A.M., M.C.), Istituto Dermopatico dell’Immacolata, Rome; Department of Pathology (R.M., G.O.), University of Parma; and Institute of Internal Medicine and Department of Biomedical Sciences (P.M.), University of Sassari, Italy.

Correspondence to Paolo Madeddu, MD, Institute of Internal Medicine, University of Sassari, Viale S Pietro 8, 07100 Sassari, Italy. E-mail madeddu@ssmain.uniss.it or madeddu{at}yahoo.com

Abstract—Knockout mice (B₂^-/-) lacking the bradykinin (BK) B₂ receptor gene develop mild hypertension, cardiac hypertrophy, and myocardial damage. We hypothesized that these effects are due to the hypertrophying and damaging actions of angiotensin II (Ang II) in the absence of the balancing protection of BK. To verify this hypothesis, B₂^-/- or wild-type mice (B₂^+/+) were administered a nonpeptide antagonist of Ang II type 1 (AT₁) receptors (A81988) from conception through 180 days of age. Untreated B₂^+/+ and B₂^-/- served as controls. Blood pressure (BP) and heart rate were monitored with the use of tail-cuff plethysmography at regular intervals. Ventricular weights, diameters, wall thickness, chamber volume, and myocardial fibrosis were measured at 40 and 180 days. No differences were observed in BP, heart rate, and cardiac weight and dimensions between treated and untreated B₂^+/+. The BP of AT₁ antagonist–treated B₂^-/- was reduced until 70 days; then, it increased to the levels found in untreated B₂^-/-. AT₁ receptor blockade resulted in a reduction in left ventricular mass, chamber volume, and wall thickness and abrogated myocardial fibrosis in B₂^-/-. These results indicate that Ang II is the major factor responsible for ventricular remodeling and myocardial damage in mice with disruption of BK B₂ receptor signaling. The interaction of Ang II and BK appears to be essential for the development of a normal heart.

Key Words: bradykinin • angiotensin II • myocardium • hypertrophy • heart failure • blood pressure • genes

This article has been cited by other articles:

				D. C. Isbell, S. Voros, Z. Yang, J. M. DiMaria, S. S. Berr, B. A. French, F. H. Epstein, S. P. Bishop, H. Wang, R. J. Roy, et al. Interaction between bradykinin subtype 2 and angiotensin II type 2 receptors during post-MI left ventricular remodeling Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3372 - H3378. [Abstract] [Full Text] [PDF]

				L. J. Mullins, M. A. Bailey, and J. J. Mullins Hypertension, Kidney, and Transgenics: A Fresh Perspective Physiol Rev, April 1, 2006; 86(2): 709 - 746. [Abstract] [Full Text] [PDF]

				Y. Ikeda, I. Hayashi, E. Kamoshita, A. Yamazaki, H. Endo, K. Ishihara, S. Yamashina, Y. Tsutsumi, H. Matsubara, and M. Majima Host Stromal Bradykinin B2 Receptor Signaling Facilitates Tumor-Associated Angiogenesis and Tumor Growth Cancer Res., August 1, 2004; 64(15): 5178 - 5185. [Abstract] [Full Text] [PDF]

				G. Bledsoe, L. Chao, and J. Chao Kallikrein gene delivery attenuates cardiac remodeling and promotes neovascularization in spontaneously hypertensive rats Am J Physiol Heart Circ Physiol, October 1, 2003; 285(4): H1479 - H1488. [Abstract] [Full Text] [PDF]

				A. H. Schmaier The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2003; 285(1): R1 - R13. [Abstract] [Full Text] [PDF]

				R. Maestri, A. F. Milia, M. B. Salis, G. Graiani, C. Lagrasta, M. Monica, D. Corradi, C. Emanueli, and P. Madeddu Cardiac Hypertrophy and Microvascular Deficit in Kinin B2 Receptor Knockout Mice Hypertension, May 1, 2003; 41(5): 1151 - 1155. [Abstract] [Full Text] [PDF]

				F. Trabold, S. Pons, A. A. Hagege, M. Bloch-Faure, F. Alhenc-Gelas, J.-F. Giudicelli, C. Richer-Giudicelli, and P. Meneton Cardiovascular Phenotypes of Kinin B2 Receptor- and Tissue Kallikrein-Deficient Mice Hypertension, July 1, 2002; 40(1): 90 - 95. [Abstract] [Full Text] [PDF]

				S. C. Supowit, H. Zhao, and D. J. DiPette Nerve Growth Factor Enhances Calcitonin Gene-Related Peptide Expression in the Spontaneously Hypertensive Rat Hypertension, February 1, 2001; 37(2): 728 - 732. [Abstract] [Full Text] [PDF]

				M. de Gasparo, K. J. Catt, T. Inagami, J. W. Wright, and Th. Unger International Union of Pharmacology. XXIII. The Angiotensin II Receptors Pharmacol. Rev., September 1, 2000; 52(3): 415 - 472. [Abstract] [Full Text] [PDF]